Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorvotuzumab Mertansine in CD56+ Hematological Malignancies
NCT02420873Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of lorvotuzumab mertansine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), aggressive natural killer-cell leukemia (ANKL), acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started May 2015; status: completed.
02
Drugs
lorvotuzumab mertansine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)aggressive natural killer-cell leukemia (ANKL)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT02420873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420873.